Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma

Br J Haematol. 2006 Jul;134(2):180-3. doi: 10.1111/j.1365-2141.2006.06141.x. Epub 2006 Jun 1.

Abstract

Genetic variation in innate immunity may alter host-pathogen defence mechanisms and promote aberrant immune responses and non-Hodgkin lymphoma (NHL). To test this hypothesis, we investigated polymorphisms in innate immune genes in a pooled analysis of two population-based case-control studies of NHL from the San Francisco Bay Area (308 cases, 684 controls) and UK (596 cases, 758 controls). The caspase recruitment domain-containing protein 1007fs homozygote variant was positively associated with NHL risk (odds ratios (OR) = 3.1, 95% confidence intervals (CI) 1.1-8.8), whereas the toll-like receptor 4 1063A>G variant allele was inversely associated with diffuse large cell lymphoma (OR = 0.67, 95% CI 0.45-0.99). These results suggest that variation in innate immune genes may alter NHL susceptibility.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Case-Control Studies
  • Genetic Predisposition to Disease
  • Genotype
  • Humans
  • Immunity, Innate / genetics*
  • Intracellular Signaling Peptides and Proteins / genetics
  • Lymphoma, Non-Hodgkin / genetics*
  • Lymphoma, Non-Hodgkin / immunology
  • Neoplasm Proteins / genetics
  • Nod2 Signaling Adaptor Protein
  • Polymorphism, Single Nucleotide*
  • Toll-Like Receptor 4 / genetics

Substances

  • Intracellular Signaling Peptides and Proteins
  • NOD2 protein, human
  • Neoplasm Proteins
  • Nod2 Signaling Adaptor Protein
  • TLR4 protein, human
  • Toll-Like Receptor 4